Prospective Data on Stereotactic Ablative Radiotherapy Provides Guidance in an Unusual Clinical Scenario
Mené sur 32 patients atteints d'un cancer du poumon non à petites cellules de stade précoce et présentant une maladie pulmonaire interstitielle (âge médian : 78 ans ; 59 % d'hommes), cet essai international de phase II évalue l'efficacité, du point de vue de la survie globale médiane, d'une radiochirurgie
Conventional wisdom of oncologic principles guides oncology practices, particularly in terms of balancing the potential risks and benefits of therapy. By the Hippocratic Oath, physicians “first do no harm”; however, both patients and physicians routinely accept some risk with oncologic therapies in hopes of prolongation of life and cure. The treatment of early-stage non–small cell lung cancer (NSCLC) in patients with interstitial lung disease (ILD) is a relatively unusual clinical scenario for which it has been historically challenging to balance the risks and benefits of therapy (due to low pulmonary reserve and a likely low tolerance for pulmonary toxic effects).
JAMA Oncology , éditorial, 2023